Reviewing CymaBay Therapeutics Inc. (CBAY)’s and Jaguar Health Inc. (NASDAQ:JAGX)’s results

As Biotechnology companies, CymaBay Therapeutics Inc. (NASDAQ:CBAY) and Jaguar Health Inc. (NASDAQ:JAGX) are our subject to compare. And more specifically their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CymaBay Therapeutics Inc. 2 0.00 46.33M -1.43 0.00
Jaguar Health Inc. 1 0.00 10.23M -89.52 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 provides the return on equity, net margins and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
CymaBay Therapeutics Inc. 2,515,883,790.39% -42.4% -39.3%
Jaguar Health Inc. 1,534,423,278.84% -899.6% -126.1%

Risk and Volatility

CymaBay Therapeutics Inc. has a 1.1 beta, while its volatility is 10.00%, thus making it more volatile than Standard and Poor’s 500. Competitively, Jaguar Health Inc. is 34.00% less volatile than Standard and Poor’s 500, because of the 0.66 beta.


The Current Ratio of CymaBay Therapeutics Inc. is 13.1 while its Quick Ratio stands at 13.1. The Current Ratio of rival Jaguar Health Inc. is 0.9 and its Quick Ratio is has 0.6. CymaBay Therapeutics Inc. is better equipped to clear short and long-term obligations than Jaguar Health Inc.

Analyst Ratings

CymaBay Therapeutics Inc. and Jaguar Health Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
CymaBay Therapeutics Inc. 0 1 0 2.00
Jaguar Health Inc. 0 0 2 3.00

CymaBay Therapeutics Inc.’s upside potential currently stands at 6.38% and an $2 consensus target price. Meanwhile, Jaguar Health Inc.’s consensus target price is $4, while its potential upside is 404.22%. The information presented earlier suggests that Jaguar Health Inc. looks more robust than CymaBay Therapeutics Inc. as far as analyst opinion.

Institutional and Insider Ownership

The shares of both CymaBay Therapeutics Inc. and Jaguar Health Inc. are owned by institutional investors at 95% and 9.3% respectively. 0.2% are CymaBay Therapeutics Inc.’s share owned by insiders. Insiders Comparatively, owned 13.23% of Jaguar Health Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CymaBay Therapeutics Inc. -0.57% -69.08% -71.07% -84.22% -79.77% -77.76%
Jaguar Health Inc. -4.84% -24.41% -48.63% -92.22% -97.73% -96.38%

For the past year CymaBay Therapeutics Inc.’s stock price has smaller decline than Jaguar Health Inc.


On 9 of the 11 factors CymaBay Therapeutics Inc. beats Jaguar Health Inc.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. It engages in developing seladelpar (MBX-8025), a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes. CymaBay Therapeutics Inc. has licensing agreement with Kowa Pharmaceuticals America, Inc. for the development and commercialization of arhalofenate in the United States; development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products containing halofenate, its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics Inc. was incorporated in 1988 and is headquartered in Newark, California.

Napo Pharmaceuticals, Inc., a human health company, focuses on developing and commercializing novel gastrointestinal prescription products from plants. Its products include Mytesi, an FDA approved product for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Napo Pharmaceuticals, Inc. was formerly known as PS Pharmaceuticals, Inc. The company was founded in 2001 and is based in San Francisco, California.